Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Nov 7, 2022--
The "Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), End-user (Lab, PoC, Academia) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period.
Troponin I and T estimated held the largest share of cardiac marker testing market in 2021, by Biomarker Type
Based on biomarker type, the cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide (BNP and Nt-proBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment accounted for the largest share of 51.1 % of the cardiac marker testing market in 2021.
Factors such as high sensitivity and specificity, long elevation time (rises over 4-8 hours, peaks at 10-24 hours, and declines over ten days), and rapid prediction of outcomes are driving the growth of this segment. In addition, lab technicians are more familiar with the use of these markers as compared to other biomarkers
Laboratory testing facilities segment accounted for the largest share of the cardiac marker testing market in 2021, by End user
Based on end users, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2021, the laboratory testing facilities segment accounted for the largest share of 61.4% of the global cardiac marker testing market. Factors such as high testing throughput, better sensitivity & diagnostic accuracy compared to POC testing, and high preference for laboratory testing over POCT testing are driving the growth of this segment.
The Asia Pacific market to grow at the highest CAGR during the forecast period
The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period.
The Asia Pacific market is driven due rising growing investments by government agencies in emerging countries of Asia Pacific for the improvement of healthcare infrastructure, growing number of independent clinical laboratories, presence of large patient population, and strategies adopted by players to increase their cardiac testing product reach in Asia Pacific.
Market Dynamics
Drivers
Restraints
Opportunities
Challenges
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/6w8zcp
View source version on businesswire.com:https://www.businesswire.com/news/home/20221107005580/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH CARDIOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 11/07/2022 05:50 AM/DISC: 11/07/2022 05:51 AM
http://www.businesswire.com/news/home/20221107005580/en